Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Cerus Corporation to Release Third Quarter 2021 Financial Results on November 2, 2021


Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international).

A replay will be available on Cerus' website, or by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and entering conference ID number 3970817. The replay will be available approximately three hours after the call through November 16, 2021.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.


These press releases may also interest you

at 04:00
Coway Co., Ltd., the "Best Life Solution Company," today reported its financial results for the first quarter of 2024. "Coway continues to maintain consistent performance with a revenue that's surpassed 1 trillion won for four consecutive quarters,"...

at 04:00
COCA, the world's first MPC wallet with a non-custodial debit card, is excited to announce that Pavel Matveev, the Founder of Wirex, a leading Web3 money app, has joined its team as a Strategy and Product Advisor. Under the visionary leadership of...

at 04:00
CACI Limited, a leading data and technology solutions company, has acquired Rowe IT Holdings Limited ("Rowe IT"). Rowe IT provides software engineering, systems integration, data analytics and cloud technologies to a strong roster of government and...

at 04:00
ViewSonic Corp., a leading global provider of visual solutions, today announced that its ambitious targets for achieving net-zero greenhouse gas (GHG) emissions by 2050 have been validated by the Science Based Targets initiative (SBTi). This...

at 04:00
LONDON, May 10, 2024 /PRNewswire/ ? Drofa Comms, a PR firm for finance and fintech, released a special magazine as a part of an initiative encouraging women to embrace their potential and become more visible within the business community. 'Women...

at 03:54
On May 9th, Momcozy, a global leader in mother and baby care, hosted a heartwarming event at Babylist Beverly Hills as part of its "Momcozy Village" campaign. This initiative emphasizes the belief that "it takes a village to raise a mother," focusing...



News published on and distributed by: